ADAG – adagene inc. - ads, each representing 1.25 ordinary shares (US:NASDAQ)

News

ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
Adagene Provides Business Update and 2026 Objectives
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
Adagene (NASDAQ:ADAG) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Adagene (NASDAQ:ADAG) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com